Background Impairment in a wide range of cognitive abilities has been consistently reported
in individuals with schizophrenia. Both neurocognitive and social cognitive deficits are …

Purpose Older people are at risk of anticholinergic side effects due to changes affecting drug
elimination and higher sensitivity to drug's side effects. Anticholinergic burden scales (ABS) …

Objective: Many psychotropic medications used to treat schizophrenia have significant
anticholinergic properties, which are linked to cognitive impairment and dementia risk in …

Cognitive impairments are pervasive and disabling features of schizophrenia. Targeted
cognitive training (TCT) is a “bottom-up” cognitive remediation intervention with efficacy for …

Cognitive impairment represents one of the core features of schizophrenia, involves both
neurocognition and social cognition domains, and has a significant negative impact on real …

Methods Participants in the COGS-2 study have previously been described, including
inclusion and exclusion criteria (29). Participants were either healthy control subjects (HCS …

Background Anticholinergic drugs are commonly prescribed, especially to older adults.
Anticholinergic burden scales (ABS) have been used to evaluate the cumulative effects of …

Background Patients with schizophrenia constitute a particularly vulnerable group for oral
diseases. Among the different factors involved, we aimed to examine the evidence of how …

The integration of pharmacotherapy with psychosocial interventions has an important role to
play in the improvement of functional outcome of subjects with schizophrenia (SCZ), in all …

BACKGROUND: Long-term prescribing of anticholinergic medications (ACM) for
antipsychotic-associated extrapyramidal symptoms (EPS) is not recommended, yet is widely …